Anneleen Beckers
Overview
Explore the profile of Anneleen Beckers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
786
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhai L, Balachandran A, Larkin R, Seneviratne J, Chung S, Lalwani A, et al.
Int J Mol Sci
. 2023 Nov;
24(21).
PMID: 37958555
amplification occurs in approximately 20-30% of neuroblastoma patients and correlates with poor prognosis. The transgenic mouse model mimics the development of human high-risk neuroblastoma and provides strong evidence for the...
2.
De Wyn J, Zimmerman M, Weichert-Leahey N, Nunes C, Cheung B, Abraham B, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638267
Roughly half of all high-risk neuroblastoma patients present with MYCN amplification. The molecular consequences of MYCN overexpression in this aggressive pediatric tumor have been studied for decades, but thus far,...
3.
Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, et al.
World J Urol
. 2018 Dec;
37(12):2557-2564.
PMID: 30578441
Purpose: Patients with oligometastatic prostate cancer (PC) may benefit from metastasis-directed therapy (MDT), delaying disease progression and the start of palliative systemic treatment. However, a significant proportion of oligometastatic PC...
4.
Ooi C, Carter D, Liu B, Mayoh C, Beckers A, Lalwani A, et al.
Cancer Res
. 2018 Apr;
78(12):3122-3134.
PMID: 29610116
Neuroblastoma is a pediatric cancer of the sympathetic nervous system where amplification is a key indicator of poor prognosis. However, mechanisms by which MYCN promotes neuroblastoma tumorigenesis are not fully...
5.
De Wilde B, Beckers A, Lindner S, Kristina A, De Preter K, Depuydt P, et al.
Oncotarget
. 2018 Mar;
9(9):8334-8349.
PMID: 29492199
Genetically engineered mouse models have proven to be essential tools for unraveling fundamental aspects of cancer biology and for testing novel therapeutic strategies. To optimally serve these goals, it is...
6.
Jacobs B, Goetghebeur E, Vandesompele J, De Ganck A, Nijs N, Beckers A, et al.
Anal Chem
. 2017 Mar;
89(8):4461-4467.
PMID: 28350455
Standard data analysis pipelines for digital PCR estimate the concentration of a target nucleic acid by digitizing the end-point fluorescence of the parallel micro-PCR reactions, using an automated hard threshold....
7.
Henssen A, Odersky A, Szymansky A, Seiler M, Althoff K, Beckers A, et al.
Oncotarget
. 2016 Nov;
8(1):430-443.
PMID: 27888795
Neuroblastoma is the most common extracranial tumor in children. Despite aggressive multimodal treatment, high-risk neuroblastoma remains a clinical challenge with survival rates below 50%. Adding targeted drugs to first-line therapy...
8.
Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, et al.
Oncotarget
. 2016 Aug;
7(41):66344-66359.
PMID: 27572323
The systemic and resistant nature of metastatic neuroblastoma renders it largely incurable with current multimodal treatment. Clinical progression stems mainly from the increasing burden of metastatic colonization. Therapeutically inhibiting the...
9.
Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis
Carter D, Sutton S, Pajic M, Murray J, Sekyere E, Fletcher J, et al.
Mol Oncol
. 2016 Mar;
10(6):866-78.
PMID: 26996379
The MYCN gene is amplified and overexpressed in a large proportion of high stage neuroblastoma patients and has been identified as a key driver of tumorigenesis. However, the mechanism by...
10.
Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, et al.
Clin Cancer Res
. 2015 Dec;
22(10):2470-81.
PMID: 26631615
Purpose: Targeting BET proteins was previously shown to have specific antitumoral efficacy against MYCN-amplified neuroblastoma. We here assess the therapeutic efficacy of the BET inhibitor, OTX015, in preclinical neuroblastoma models...